  Resource Table.                      
  ------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Unique stem cell line identifier     CRMi001-A-1
  Alternative name(s) of stem          SANFi002-A-1
  cell line                            CRMi001-A-1-CLTA-TQ2
                                       NCRM-5-CLTA-TQ2
  Institution                          Sanford Research
  Contact information of distributor   Kevin Francis; <Kevin.Francis@SanfordHealth.org>
  Type of cell line                    iPSC
  Origin                               Human
  Additional origin info               Age: Fetal
                                       Sex: Male
                                       Ethnicity if known: Unknown
  Cell Source                          Umbilical cord blood derived CD34 + cells
  Clonality                            Mixed
  Method of reprogramming              Episomal vectors: Oct4, Sox2, c-Myc, KLF4, Lin28 SV40 Large T antigen
  Genetic Modification                 Yes
  Type of Modification                 Knock-in
  Associated disease                   N/A
  Gene/locus                           CLTA/9p13.3
  Method of modification               CRISPR/Cas9
  Name of transgene or resistance      Tq2 and puromycin resistance gene
  Inducible/constitutive system        N/A
  Date archived/stock date             05/30/17
  Cell line repository/bank            N/A
  Ethical approval                     The CRMi001-A hiPSC line was obtained from the National Heart, Lung, and Blood Institute iPSC Core in Bethesda, MD. All research involving hiPSCs was approved by the Institutional Biosafety Committee at Sanford Research (approval no. 2015101).

Resource utility {#S1}
================

Generation of CRMi001-A-1 human induced pluripotent stem cells enable monitoring and manipulation of endogenous clathrin trafficking dynamics in pluripotent or differentiated cell types.

Resource details {#S2}
================

A CRISPR/Cas9 mediated knock-in system was utilized to generate human induced pluripotent stem cells (hiPSCs) expressing CLTA tagged with the fluorescent protein Turquoise2 (Tq2), followed by a self-cleavable P2A peptide sequence and the puromycin *N*-acetyltransferase gene. 1kB homology arms targeted a Tq2-P2A-puro cassette to the C-terminal end of the *CLTA* locus ([Fig. 1A](#F1){ref-type="fig"}). A single guide RNA (sgRNA) was designed to target the stop codon in Exon 7 and demonstrated efficient cleavage in a T7 endonuclease assay ([Fig. S1](#SD1){ref-type="supplementary-material"}). CRMi001-A hiPSCs were transfected with the knock-in vector and sgRNA/Cas9 expression plasmid by nucleofection. Selection for Tq2 positive cells by fluorescence-activated cell sorting (FACS) demonstrated a knock-in efficiency of approximately 1% ([Fig. S2A](#SD1){ref-type="supplementary-material"}) and co-localized expression with clathrin heavy chain protein CLTC ([Fig. S2B](#SD1){ref-type="supplementary-material"}). As a control for random integration, CRMi001-A hiPSCs were transfected with the knock-in vector alone by nucleofection. Tq2 positive cells were collected and pooled to minimize potential off-targeting effects. Knock-in to the *CLTA* locus was validated by PCR and Sanger sequencing ([Fig. 1B](#F1){ref-type="fig"}). Targeted integration to the C-terminus of *CLTA* was confirmed by PCR analysis of edited versus unedited cells using a primer pair specific to the donor cassette and the genomic region outside of the homology arms ([Fig. 1F-1, F-2](#F1){ref-type="fig"}). PCR amplification with primers designed to span the homology arms suggested predominately heterozygous insert integration ([Fig. 1F-3](#F1){ref-type="fig"}).

CRMi001-A-1 hiPSCs maintained human pluripotent stem cell-like morphology ([Fig. 1C](#F1){ref-type="fig"}, [Table 1](#T2){ref-type="table"}). Pluripotency of the CRMi001-A-1 line was confirmed by immunofluorescent expression of transcription factors Oct4A, Nanog, and Sox2, as well as surface markers SSEA4, TRA-1-60 and TRA-1-81 ([Fig. 1E](#F1){ref-type="fig"}), and FACS quantitation of Oct4A-Alexa Fluor 488 expression ([Fig. 1D](#F1){ref-type="fig"}). Pluripotency was further confirmed by embryoid body (EB) formation, loss of pluripotent transcription expression (*POU5F1*) and spontaneous germ layer differentiation exhibited by expression of endodermal (*AFP*), mesodermal (*TBXT*), and ectodermal (*MSI1*) markers ([Fig. 1H](#F1){ref-type="fig"}) assessed by qRT-PCR. Transcript levels were normalized to GAPDH expression and plotted relative to expression levels in respective hiPSC lines. Directed neural differentiation confirmed ectodermal potential through expression of human-specific Nestin (hNestin), expressed by human neural progenitors, and the neuronal-specific intermediate filament, Neurofilament, medium-chain polypeptide (NF-M) ([Fig. 1I](#F1){ref-type="fig"}). Karyotypic analysis detected no chromosomal abnormalities ([Fig. 1G](#F1){ref-type="fig"}) and hiPSCs were mycoplasma free ([Fig. S3](#SD1){ref-type="supplementary-material"}). Authentication of CRMi001-A-1 hiPSCs was verified by short tandem repeat analysis in comparison to parental CRMi001-A hiPSCs at 17 distinct loci (submitted in archive with journal).

Materials and methods {#S3}
=====================

Cell culture {#S4}
------------

hiPSCs were cultured in StemMACS iPS-Brew XF medium (Miltenyi Biotec) on Corning™ Matrigel™ hESC-qualified-coated plates. Cells were maintained at 37 °C in humidified 5% CO~2~ and 21% O~2~. hiPSCs were passaged every 5 days with 0.5 mM EDTA.

Targeting of the CLTA locus {#S5}
---------------------------

sgRNAs targeting the *CLTA* locus were designed at [crispr.mit.edu](crispr.mit.edu). An oligo pair, 5'-CACCGCAGATGTAGTGTTTCCACA-3′ and 3'-CGTCTACA TCACAAAGGTGTCAAA-5′, was annealed and subcloned into the pX330-U6-Chimeric_BB-CBh-hSpCas9 vector (kind gift from Feng Zheng). sgRNA activity was validated by T7 endonuclease assay.

1kB homology arms flanking the Turquoise2-P2A-puromyocin insert ([Fig. 1A](#F1){ref-type="fig"}) were amplified from genomic DNA and inserted into the pDONOR3 vector by Golden gate assembly ([@R1]). To prevent Cas9 recognition after integration, the insert\'s PAM sequence was mutated ([Table 1](#T2){ref-type="table"}).

1 × 10^6^ CRMi001-A hiPSCs were transfected using the Nucleofector 2b system, Nucleofector Kit V, 4 μg donor vector and 2.5 μg sgRNA/Cas9 vector. hiPSCs were plated onto Matrigel-coated plates in iPSC-Brew XF. Tq2 positive cells were isolated with a BD FACSJazz Cell Sorter.

Targeted integration analysis {#S6}
-----------------------------

Homology-directed repair was validated by PCR utilizing primers listed in [Table 2](#T3){ref-type="table"}. CRMi001-A hiPSCs transfected with donor vector alone were used to control for non-selective integration. The knock-in was sequenced entirely (3′ and 5′ targeting in [Fig. 1B](#F1){ref-type="fig"}).

Karyotyping, STR analysis, and mycoplasma detection {#S7}
---------------------------------------------------

G-banding karyotype analysis (450 band resolution) of eight cells was performed by the Sanford Cytogenetics Laboratory. STR analysis was performed using the ATCC Cell Line Authentication Service and compared to the CRMi001-A line. Mycoplasma assessment was performed using a PCR Detection Kit (Applied Biological Materials).

Immunocytochemistry {#S8}
-------------------

hiPSCs were grown on Matrigel-coated chamberslides, fixed with 4% paraformaldehyde, permeabilized with 0.2% Trition X-100, and incubated in blocking buffer (0.1% Triton X-100, 5% donkey serum). Primary antibodies were incubated overnight at 4 °C in blocking buffer. Alexa Fluor conjugated secondary antibodies and Hoechst counterstain were incubated for 1 hr at room temperature. Images were taken using a Nikon NiE fluorescent microscope and processed using NIS Elements software and Adobe Photoshop.

Quantitative analysis of pluripotency {#S9}
-------------------------------------

hiPSCs were dissociated with accutase and fixed in 2% paraformaldehyde overnight at 4 °C. Cells were incubated with Alexa Fluor 488-conjugated Oct4A and analyzed on a BD LSRFortessa.

Germ layer differentiation {#S10}
--------------------------

hiPSCs were incubated with 10 μM Y27632 prior to accutase dissociation. 1 × 10^6^ cells were plated into the AggreWell™800 system (Stem Cell Technologies). After 5 days in differentiation media (DMEM/F12, 20% Knockout Serum Replacement, 2 mM [l]{.smallcaps}-glutamine, 1% NEAA, 1000 units/mL Penicillin-streptomycin, 100 μM β-mercaptoethanol), aggregates were transferred to gelatinized plates and spontaneously differentiated for 10 days.

Directed neural differentiation {#S11}
-------------------------------

Neural rosettes were isolated from EBs, plated onto laminin/PLO coated coverslips and differentiated for 7 days toward neural lineages.

Real-time PCR analysis {#S12}
----------------------

RNA was isolated using the E.Z.N.A RNA Kit (Omega Biotek). 1 μg of RNA was reverse transcribed using the Superscript III First-Strand Synthesis System (Invitrogen). Quantitative PCR was performed with Absolute Blue qPCR Master Mix on an Applied Biosystems 7500 instrument. Samples were analyzed in triplicate from independent experiments. Transcript abundance was normalized to GAPDH and quantified using the 2^−ΔΔCt^ method. Primers used are listed in [Table 2](#T3){ref-type="table"}.
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Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2018.10.001>.
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###### 

Characterization and validation.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classification               Test                                                          Result                                                                                                            Data
  ---------------------------- ------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ---------------------------------------------
  Morphology                   Photography                                                   Normal hiPSC morphology                                                                                           [Fig. 1](#F1){ref-type="fig"} Panel C

  Phenotype                    Qualitative analysis                                          Immunohistochemistry of pluripotency markers: Oct4A, Nanog, Sox2, TRA-1-60, TRA-1-81                              [Fig. 1](#F1){ref-type="fig"} Panel E

                               Quantitative analysis                                         Expression of pluripotency marker Oct4 by flow cytometry                                                          [Fig. 1](#F1){ref-type="fig"} Panel D

  Genotype                     Karyotype (G-banding) and resolution                          Normal Karyotype: 46,XY, resolution: 480 band level                                                               [Fig. 1](#F1){ref-type="fig"} Panel G

  Identity                     STR analysis                                                  17 loci tested, 100% match                                                                                        Submitted in archive with journal

  Mutation analysis (IF        PCR and sequencing                                            Heterozygous targeted integration                                                                                 [Fig. 1](#F1){ref-type="fig"} Panel F

  APPLICABLE)                  Southern Blot OR WGS                                          Not performed. Top 10 predicted coding and non-coding off-targets were sequenced, detecting no indel formation.   Available by request

  Microbiology and virology    Mycoplasma                                                    Mycoplasma testing by PCR: Negative                                                                               Supplementary Fig. 4

  Differentiation potential    Embryoid body formation and Directed neural differentiation   Expression of genes from three germ layers following spontaneous differentiation: *AFP, TBXT, MSI1*\              [Fig. 1](#F1){ref-type="fig"} Panel H and I
                                                                                             Directed neural differentiation immunohistochemistry: Human\                                                      
                                                                                             Nestin, Medium-length neurofilament polypeptide                                                                   

  Donor screening (OPTIONAL)   HIV 1 + 2 Hepatitis B, Hepatitis C                            Not performed                                                                                                     N/A

  Genotype additional info     Blood group genotyping                                        Not performed                                                                                                     N/A

    (OPTIONAL)                 HLA tissue typing                                             Not performed                                                                                                     N/A
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Reagents details

  Antibodies used for immunocytochemistry/flow-cytometry                                                                                 
  -------------------------------------------------------- -------------------------------------------------------------------- -------- ---------------------------------------------------------
  Pluripotency markers                                     Rabbit anti-OCT4                                                     1:400    Cell Signaling Technology Cat\# 2840, RRID:AB_2167691
                                                           Mouse anti-SSEA4                                                     1:400    Cell Signaling Technology Cat\# 4755, RRID:AB_1264259
                                                           Rabbit anti-NANOG                                                    1:200    Cell Signaling Technology Cat\# 4903, RRID:AB_10559205
                                                           Mouse anti-TRA-1-60                                                  1:400    Cell Signaling Technology Cat\# 4746, RRID:AB_2119059
                                                           Rabbit anti-SOX2                                                     1:200    Cell Signaling Technology Cat\# 3579, RRID:AB_2195767
                                                           Mouse anti-TRA-1-81                                                  1:400    Cell Signaling Technology Cat\# 4745P, RRID:AB_10829904
  Differentiation markers                                  Mouse anti-human Nestin                                              1:1000   Molecular Probes Cat\# A-31572, RRID:AB_162543
                                                           Rabbit anti-Neurofilament M, CT                                      1:1000   Millipore Cat\# MAB5326, RRID:AB_11211837
  Secondary antibodies                                     Alexa Fluor 555 donkey anti-rabbit IgG (H + L)                       1:1000   Molecular Probes Cat\# A-31572, RRID:AB_162543
                                                           Alexa Fluor 488 goat anti-mouse IgG (H + L)                          1:1000   Thermo Fisher Scientific Cat\# A-11001, RRID:AB_2534069
                                                           Alexa Fluor 647 goat anti-rabbit IgG (H + L)                         1:1000   Thermo Fisher Scientific Cat\# A-21244, RRID:AB_2535812
  Flow cytometry                                           Oct-4A (C30A3) Rabbit mAb Alexa Fluor 488 conjugate                  1:50     Cell Signaling Technology Cat\# 5177S, RRID:AB_10693303
                                                           Rabbit (DA1E) mAb IgG XP Isotype Control Alexa Fluor 488 conjugate   1:50     Cell Signaling Technology Cat\# 2975S, RRID:AB_10699151

  --------------------------------------------------------------------------------------------------------
  Primers                                                                   
  ------------------------------------------ ------------------------------ ------------------------------
  Pluripotency Markers (qPCR)                *POU5F1*                       CCAAGGAATAGTCTGTAGAAGTGC/\
                                                                            TGCATGAGTCAGTGAACAGG

  Differentiation Markers (qPCR)             *AFP*                          TCTGCATGAATTATACATTGACCAC/\
                                                                            AGGAGATGTGCTGGATTGTC

                                             *MSI1*                         TCGTTCGAGTCACCATCTTG/\
                                                                            GGCTTCGTCACTTTCATGGA

                                             *TBXT*                         CTATGTGGATTCGAGGCTCATAC/\
                                                                            CGTCTCCTTCAGCAAAGTCAA

  House-Keeping Genes (qPCR)                 *GAPDH*                        GCGCCCAATACGACCAA/\
                                                                            CTCTCTGCTCCTCCTGTTC

  Targeted integration analysis/sequencing   *PCR analysis*                 

                                             1\. Template control           TTGCTTGCCAGTGTCCCTCAGTTTA/\
                                                                            GCTTTAATAATTGCTTGGAACATCACCT

                                             2\. Tq2-Puro Integration       TACGAGCGGCTCGGCTTCA\
                                                                            GCTTTAATAATTGCTTGGAACATCACCT

                                             3\. Mono-allelic integration   ATCTTGGGAAAGCCAGAATGTCATT /\
                                                                            CCTAAACTGAGGGACACTGGCAA

                                             *Sequencing*\                  ATCTTGGGAAAGCCAGAATGTCATT\
                                             5′ targeting                   TACCAGCAGAACACCCCCAT

                                             3′ targeting                   TCACCGAGCTGCAAGAACTCTT\
                                                                            CCTAAACTGAGGGACACTGGCAA

  T7 endonuclease assay                      1 kB amplicon                  ATCTTGGGAAAGCCAGAATGTCATT\
                                                                            CCTAAACTGAGGGACACTGGCAA
  --------------------------------------------------------------------------------------------------------
